Led · Seed · Aug 2026

Cirrus Therapeutics is focused on ocular immunology and is based in Cambridge, Massachusetts. Its lead program is a preclinical adeno-associated virus (AAV) ocular gene therapy designed to restore IRAK-M, an immune regulator expressed in retinal cells. The company is targeting dry age-related macular degeneration with the goal of reversing disease and preventing progression to geographic atrophy. Cirrus has raised a seed round now totaling $14.7 million, initially announced at $11 million. Investors in the round include ClavystBio (lead), Polaris Partners, SEEDS (SG Growth Capital) and the Intellectual Property Company of Cedars-Sinai. The company is using the seed-stage capital to advance its preclinical program toward further development.

Led · Series A · Jul 2026

Respiree develops a monitoring platform called 1Bio™ that integrates FDA‑cleared wearable sensors, artificial intelligence, and electronic health record connectivity to track the condition of patients with cardio‑respiratory diseases. Its system is designed to identify early signs of clinical deterioration to enable clinicians to intervene before critical events occur, with deployments reported in both hospital and home care settings. The company says its technology contributes to reducing hospital admissions and ICU transfers. Respiree is based at the Texas Medical Center Innovation campus in Houston and benefits from the TMC HealthTech Accelerator’s clinical, regulatory, and market-access support. Current company plans, supported by the Series A proceeds, focus on U.S. commercial expansion, strengthening the Houston headquarters, and advancing the proprietary platform’s development.

Participated · Equity · Jun 2026

Leyden Labs is developing a Mucosal Protection Platform that administers broadly protective antibodies directly to the respiratory mucosa via intranasal sprays. The company targets protection against influenza, coronaviruses and other respiratory virus families with candidates designed to retain activity even as viruses mutate. Leyden Labs positions mucosal delivery as protection “at the gate,” aiming to prevent initial infection and subsequent illness where systemic vaccines or antibodies may be less effective. The approach is also presented as potentially beneficial for people with weakened immune systems because it does not rely on a fully functional systemic immune response. Leyden Labs is advancing its programs through clinical development and is focused on enabling global access to its products. The company recently added Ben Verwaayen to its Supervisory Board as it scales development and access efforts.

Participated · Series C · Jun 2026

Rejoni is focused on developing and commercializing gynecological products built on proprietary biomaterials, with its lead investigational product the Juveena Hydrogel System. Juveena is designed to reduce the incidence and severity of intrauterine adhesions by placing a temporary hydrogel spacer in the uterine cavity using a proprietary transcervical catheter. The product is investigational and pending U.S. FDA approval and is not available for sale. Rejoni is clinical-stage and plans to scale manufacturing, supply operations, and market-access and physician/patient engagement in preparation for commercial launch. The company was founded in June 2020 in Bedford, MA; Amar Sawhney is founder and chairman and John Nealon is CEO. The recent $25 million financing will support these commercialization and regulatory preparations.

Led · Series D · Jun 2025

Allay Therapeutics is a clinical-stage biotech pioneering ultra-sustained analgesic products that combine validated non-opioid analgesics (bupivacaine) with biopolymers to deliver weeks of localized pain relief. Its lead candidate, ATX101, is an investigational formulation of bupivacaine designed to provide extended analgesia after surgery and is placed at the end of standard surgery to dissolve over weeks. The company is enrolling a 200-participant Phase 2b registration trial in total knee arthroplasty (TKA) initiated in February 2025, with results anticipated in Q4 2025 and a Phase 3 planned for 2026. ATX101 previously showed durable treatment effects versus standard-of-care bupivacaine in a prior dose-ranging Phase 2b, with less opioid use and improved function, and has received FDA Breakthrough Therapy designation. Allay has R&D teams in Singapore and the U.S., and its partner Maruishi Pharmaceutical is conducting a Phase I/II safety study in Japan and has expanded its license territory to South Korea and Taiwan. Proceeds from the recent financing and venture debt will advance the ATX101 Phase 2b registration trial and the company’s broader ultra-sustained pain platform. Allay Therapeutics is developing thin, coin‑sized biodegradable implants that are placed around an implanted knee joint to deliver a validated non‑opioid local anesthetic in a controlled fashion for up to three weeks. The company’s novel active ingredient–polymer architecture extends analgesic delivery an order of magnitude beyond existing local systems and the implants gradually dissolve as they release drug. Evonik supplies the biodegradable polymers used in the devices and has invested in the company, and Allay is positioning the technology as an alternative to systemic opioids to improve and accelerate recovery. Allay’s products are in early stages of clinical development and the firm is developing a portfolio of candidates based on the same drug‑polymer architecture for other orthopedic and soft‑tissue surgeries. The technology was developed in Singapore and Allay maintains R&D facilities there while being headquartered in San Jose, California. The company highlights the large U.S. market—more than 1.2 million knee joint interventions per year and an estimated $10 billion treatment volume for severe postoperative pain—against the backdrop of the opioid crisis. Allay Therapeutics is a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation. Its proprietary platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates that deliver targeted pain relief over weeks. The company’s lead candidate, ATX-101, is being advanced into a Phase 2b study in total knee arthroplasties in the United States. R&D teams in Singapore and the Bay Area have developed proof-of-concept implant variants, injectable formulations, on-demand self-dosing formulations, and formulations incorporating additional small molecules and local analgesics. Allay intends to advance at least one new clinical candidate into trials each year and is building manufacturing capabilities in the Bay Area to support future product launches. The company completed an oversubscribed $60M Series C to support clinical and platform development.